AngelaJ.ZiebarthMD(She/Her)

PubMed

• 11 citations
  Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy.
  Angela Ziebarth, Haller J. Smith, Mary E. Killian, Nguyet A. Nguyen, Jennifer K. Durst
  Gynecologic Oncology. 2012-07-01
• 46 citations
  Endoglin (CD105) Contributes to Platinum Resistance and Is A Target for Tumor-Specific Therapy in Epithelial Ovarian Cancer
  Angela Ziebarth, Somaira Nowsheen, Adam D. Steg, Monjri Shah, Ashwini A. Katre
  Clinical Cancer Research. 2013-01-01
• 77 citations
  Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer
  Adam D. Steg, Ashwini A. Katre, Kerri S. Bevis, Angela Ziebarth, Zachary C. Dobbin
  Molecular Cancer Therapeutics. 2012-05-02

Journal Articles

• Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer  
  Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner MB, Yang ES, Landen CN Jr, Clin Cancer Res, 1/1/2013

Books/Book Chapters

• Gynecologic Oncology: Clinical Practice and Surgical Atlas. 
  Chapter: Cervical Cancer. 
  Ziebarth A, Kim K, Huh W.Editors: Karlan, Bristow and Li..Edition 1st,
• Gynecologic Oncology: Clinical Practice and Surgical Atlas 
  Chapter: Cervical Cancer 
  Ziebarth A, Kim K, Huh WEditors: Karlan, Bristow and Li.2012

Abstracts/Posters

• Uterine Carcinosarcoma as a Cancer Cluster
  Williams B, Ziebarth A, Burns, J, Annual Meeting of the American Congress of Obstetricians and Gynecologists, 1/7/2017
• Use of Phenazopyridine in Visualizing Ureteral Jet Stream During Cystoscopy
  Antonetti A, Williams B, Ziebarth A, DeCesare S, Annual Meeting of the American Congress of Obstetricians and Gynecologists, 1/7/2016
• Primary ovarian cancer murine xenografts maintain tumor heterogeneity and biologically correlate with patient response to primary chemotherapy
  Ziebarth A, Dobbin Z, Katre A, Steg A, Alvarez R, Conner M, Landen C, Annual Meeting of the Society of Gynecologic Oncologists, 1/24/2012
• Cervical cancer in women 25 years and younger: An entirely different disease
  Kim K, Gunn D, Smith H, Ziebarth A, Huh W, Annual Meeting of the Society of Gynecologic Oncologists, 1/24/2012
• A novel role for the TGF-B co-receptor endoglin (CD105) in platinum resistant epithelial ovarian cancer
  Ziebarth A, Steg A, Bevis K, Katre A, Nowsheen S, Sood A, Han M, Conner E, Yang E, Landen C, Annual Meeting of the Society of Gynecologic Oncologists, 1/24/2012
• Decoy receptor 3 (DcR3) inhibits intratumoral lymphocytic infiltration by inhibiting Gm induced chemokine production in ovarian cancer
  Onujiogu N, Felder M, Kapur A, Ziebarth A, Connor, J, Annual Meeting of the Society of Gynecologic Oncologists, 1/24/2012
• Virus Capsids as Targeted Nanoparticle Drug Delivery Systems
  Morris, D. Ziebarth A, Kosuge H, O�Neill A, McConnell M, Landen C, Bellis S, Douglas T, Prevelige P, Gordan Kenan Physical Virology Conference, 1/15/2011
• The ubiquitin ligase EDD mediates platinum resistance and is a target for therapy in epithelial ovarian cancer
  Ziebarth A, Zheng H, Bradley A, Sakati W, Eier S, Lopez-Berestein S, Sood A, Eblen S, Landen C, Annual Meeting of the Society of Gynecologic Oncologists, 1/6/2011
• Targeting the Hedgehog pathway reverses taxane resistance in ovarian cancer
  Ziebarth A, Steg A, Bevis K, Alvarez R, Landen C, Annual Meeting of the Society of Gynecologic Oncologists, 1/6/2011
• Completed versus aborted radical hysterectomy for node positive stage I cervical cancer
  Ziebarth A, Durst J, Subramaniam A, Nguyen N, Smith H, Killian E, Kim K, Leath C, Straughn J, Alvarez R, Annual Meeting of the Society of Gynecologic Oncologists, 1/6/2011
• Uterine Leiomyosarcoma Express Disialoganglioside GD2 and Bind Immunocytokine 14.18 IL2; Implications for Immunotherapy
  Ziebarth A, Felder M, Harter J, Connor J, Annual Meeting of Western Association of Gynecologic Oncologists, 1/13/2009
• Join now to see all

Lectures

• Targeting Endoglin (CD105) induces apoptosis, improves platinum sensitivity both in vivo and in vitro, and is a potential therapeutic target in epithelial ovarian cancer 
  1/23/2011
• High Ascites DcR3 levels are Associated with Poor Tumor Infiltration by CD8+ Lymphocytes in Advanced Ovarian Cancer 
  1/10/2010
• Ascites DcR3 Level is Associated with Poor Prognosis in Advanced Ovarian Cancer 
  1/14/2009